Are Illumina and Beam Therapeutics the Healthcare Industry's Rising Stars?

Motley Fool2022-01-22

Illumina (NASDAQ:ILMN) and Beam Therapeutics (NASDAQ:BEAM) have at least one thing in common: They're advancing genomics, albeit in different ways. In this Motley Fool Live video recorded on Jan. 12, ...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2205825024?lang=zh_CN&edition=full","thumbnail":"","is_english":true,"pubTime":"2022-01-22 00:00","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2205825024","market":"us","top_or_hot":-1,"title":"Are Illumina and Beam Therapeutics the Healthcare Industry's Rising Stars?","media":"Motley Fool","content":"<div>\n<p>Illumina (NASDAQ:ILMN) and Beam Therapeutics (NASDAQ:BEAM) have at least one thing in common: They're advancing genomics, albeit in different ways. In this Motley Fool Live video recorded on Jan. 12, ...</p>\n\n<a href=\"https://www.fool.com/investing/2022/01/22/are-illumina-and-beam-therapeutics-the-healthcare/\">网页链接</a>\n\n</div>\n","source":"fool_stock","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Are Illumina and Beam Therapeutics the Healthcare Industry's Rising Stars?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAre Illumina and Beam Therapeutics the Healthcare Industry's Rising Stars?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-01-22 00:00 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2022/01/22/are-illumina-and-beam-therapeutics-the-healthcare/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Illumina (NASDAQ:ILMN) and Beam Therapeutics (NASDAQ:BEAM) have at least one thing in common: They're advancing genomics, albeit in different ways. In this Motley Fool Live video recorded on Jan. 12, ...</p>\n\n<a href=\"https://www.fool.com/investing/2022/01/22/are-illumina-and-beam-therapeutics-the-healthcare/\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4548","symbol_name":"巴美列捷福持仓","start_time":0,"source_url":"https://www.fool.com/investing/2022/01/22/are-illumina-and-beam-therapeutics-the-healthcare/","article_id":"2205825024","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2205825024","pubTimestamp":1642780800,"sourceInfo":{"source_id":"fool_stock","name":"Motley Fool"},"weMediaInfo":null,"summary":"One is a rising star. The other might be more like a constellation.","collect":0,"end_time":0,"defaultTopTitle":"fool.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4548":"巴美列捷福持仓","BK4535":"淡马锡持仓","ILMN":"Illumina","BK4121":"生命科学工具和服务","BK4534":"瑞士信贷持仓"},"translate_title":"Illumina和Beam治疗是医疗保健行业的后起之秀吗？","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ILMN":1},"content_text":"Illumina (NASDAQ:ILMN) and Beam Therapeutics (NASDAQ:BEAM) have at least one thing in common: They're advancing genomics, albeit in different ways. In this Motley Fool Live video recorded on Jan. 12, 2022, Motley Fool contributors Keith Speights and Brian Orelli answer a viewer's question about whether or not the two companies are rising stars in healthcare.\n\n\nKeith Speights: Illumina, which we've talked about, and Beam Therapeutics, she says, \"Are they rising stars, and what about other CRISPR stocks?\" Are Illumina and Beam rising stars, Brian?\nBrian Orelli: Well, I mean, I think Illumina has already completely risen. It's a pretty big company.\nKeith Speights: Illumina might be a constellation, right?\nBrian Orelli: Yeah. Beam is definitely a rising star. I really like the technology. I just don't like the valuation at this price. I think they are taking on too much risk for the fact that they don't even have a drug that's in clinical trials yet. But I do like the technology. And I guess if you're willing to hold on to it long enough, it's not necessarily a bad investment. But I would like to get it at a cheaper price. And I'm definitely not going to be buying it at a $5 billion valuation.\nKeith Speights: Mabel also asks, \"What about other CRISPR stocks?\" Any other CRISPR stocks that you think are ones to really take a hard look at?\"\nBrian Orelli: I haven't really been all that hot on the first-generation CRISPR stocks, mostly just because there's a limited number of diseases where you can knock out a gene and that will solve the problem with the disease. And beyond CRISPR (Therapeutics) (NASDAQ:CRSP), there's not that many companies.\nI think they're all going to end up competing for the same sort of diseases, and they already are. A lot of them are going after sickle-cell disease, and so I think that's the take-home message for the first-generation CRISPR stocks. I'm more interested in companies like Beam, where they can do precise mutations and change mutations precisely. And so that's I think where the technology is going to end up going.\nKeith Speights: Yeah, I would agree with you there. Even though Beam Therapeutics is priced at a premium for sure, especially considering where it is in its development cycle, its technology is really promising. If it works well, then that stock is going to be worth a whole lot more than $5 billion in a few years.","kind":null,"is_publish_news":null,"is_publish_highlight":null,"is_publish_live":null,"is_publish_wemedia":null,"editions":null,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"claudebot","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.22.4","shortVersion":"4.22.4","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2205825024"}